Unassociated Document

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PEBU5t/yFRQL16E0kA8l7f9E1B3qo2Km9/g3CubQ42VRssV8ETFaBIMU+kdJtGR7 wa/94tuZtfi5zU83eCB6wA== 0000950103-07-000960.txt : 20070418 0000950103-07-000960.hdr.sgml : 20070418 20070418162452 ACCESSION NUMBER: 0000950103-07-000960 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20070418 DATE AS OF CHANGE: 20070418 GROUP MEMBERS: SHUTTLE CORPORATION SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NEW RIVER PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001288379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 541816479 STATE OF INCORPORATION: VA FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-80197 FILM NUMBER: 07773698 BUSINESS ADDRESS: STREET 1: 1881 GROVE AVENUE CITY: RADFORD STATE: VA ZIP: 24141 BUSINESS PHONE: 5406337900 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - BUSINESS PHONE: 1264333455 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: - FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 SC 13D/A 1 dp05349e_sc13da.htm Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE TO

Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of

the Securities Exchange Act of 1934

(Amendment No. 5)

NEW RIVER PHARMACEUTICALS INC.

(Name of Subject Company)

SHUTTLE CORPORATION

SHIRE PLC

(Names of Filing Persons – Offeror)

Common Stock, Par Value $0.001 Per Share

(Title of Class of Securities)

648468205

(Cusip Number of Class of Securities)

Tatjana May

General Counsel

Shire plc

Hampshire International Business Park, Chineham,

Basingstoke, Hampshire, England, RG24 8EP

Telephone: +44 1256 894 000

(Name, Address and Telephone Number of Person Authorized to Receive Notices

and Communications on Behalf of Filing Persons)

Copies to:

John J. McCarthy, Jr.

Davis Polk & Wardwell

450 Lexington Avenue

New York, New York 10017

Telephone: (212) 450-4000

o	Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

x	third-party tender offer subject to Rule 14d-1.
o	issuer tender offer subject to Rule 13e-4.
o	going-private transaction subject to Rule 13e-3.
x	amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer. x

CUSIP No. 648468205

13D

Page 2 of 6 Pages

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Shuttle Corporation
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) o (b) x
3	SEC USE ONLY
4	SOURCE OF FUNDS* OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION Virginia
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER -0-
		8	SHARED VOTING POWER 35,717,806 ⁽¹⁾
		9	SOLE DISPOSITIVE POWER -0-
		10	SHARED DISPOSITIVE POWER 35,717,806 ⁽¹⁾
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 35,717,806 ⁽¹⁾
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 96.4% ⁽²⁾
14	TYPE OF REPORTING PERSON* CO

⁽¹⁾

Includes Shares tendered in the Offer by 12:00 Midnight, New York City time, on Tuesday, April 17, 2007 (not including Shares delivered through notices of guaranteed delivery).

⁽²⁾

Calculated based on 37,051,564 Shares outstanding as of April 18, 2007, as reported by New River’s transfer agent.

CUSIP No. 648468205

13D

Page 3 of 6 Pages

1	NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Shire plc
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) o (b) x
3	SEC USE ONLY
4	SOURCE OF FUNDS* OO
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
6	CITIZENSHIP OR PLACE OF ORGANIZATION England and Wales
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		7	SOLE VOTING POWER -0-
		8	SHARED VOTING POWER 35,717,806 ⁽¹⁾
		9	SOLE DISPOSITIVE POWER -0-
		10	SHARED DISPOSITIVE POWER 35,717,806 ⁽¹⁾
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 35,717,806 ⁽¹⁾
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* o
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 96.4% ⁽²⁾
14	TYPE OF REPORTING PERSON* OO

⁽¹⁾

Includes Shares tendered in the Offer by 12:00 Midnight, New York City time, on Tuesday, April 17, 2007 (not including Shares delivered through notices of guaranteed delivery).

⁽²⁾

Calculated based on 37,051,564 Shares outstanding as of April 18, 2007, as reported by New River’s transfer agent.

This Amendment No. 5 (“Amendment No. 5”) amends and supplements the Tender Offer Statement on Schedule TO (as previously amended, the “Schedule TO”) originally filed on March 2, 2007 by Shire plc, a public limited company incorporated under the laws of England and Wales (“Shire”), and Shuttle Corporation, a Virginia corporation (“Purchaser”) and an indirect wholly owned subsidiary of Shire, relating to the offer by Purchaser to purchase all outstanding shares of common stock, par value $0.001 per share (the “Shares”), of New River Pharmaceuticals Inc., a Virginia corporation (“New River”), at $64.00 per Share, net to the seller in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase dated March 2, 2007 (the “Offer to Purchase”) and in the related Letter of Transmittal (which, together with any amendments or supplements thereto, collectively constitute the “Offer”).

All capitalized terms used in this Amendment No. 5 without definition have the meanings ascribed to them in the Schedule TO.

The items of the Schedule TO set forth below are hereby amended and supplemented as follows:

Item 11. Additional Information.

Item 11 of the Schedule TO is hereby amended and supplemented by adding the following text thereto:

“The Offer expired at 12:00 Midnight, New York City time, on Tuesday, April 17, 2007. According to the Depositary, as of 12:00 Midnight, New York City time, on April 17, 2007, a total of approximately 35,717,806 Shares were validly tendered to Purchaser and not withdrawn (not including Shares delivered through notices of guaranteed delivery), representing approximately 96.4% of the Shares outstanding. Purchaser has accepted all Shares that were validly tendered and not withdrawn prior to expiration of the Offer for payment pursuant to the terms of the Offer, and payment for such Shares will be made promptly in accordance with the terms of the Offer.

On April 18, 2007, Shire issued a press release announcing the results of the Offer and announced its intention to effect, pursuant to the terms of the Merger Agreement, the Merger under the short-form merger provisions of the VSCA without prior notice to, or any action by, any other New River shareholder. At the Effective Time, each outstanding Share (other than (i) Shares owned by any wholly owned subsidiary of New River and any Shares owned by Shire, Purchaser or any wholly owned subsidiary of Shire, which shall be cancelled, or (ii) Shares owned by New River shareholders who have properly demanded appraisal under the VSCA) will be converted into the right to receive the same $64.00 in cash per Share, without interest and less any required withholding taxes, that was paid in the Offer.

The full text of Shire’s April 18, 2007 press release is attached hereto as Exhibit (a)(12).”

Item 12. Exhibits.

Item 12 of the Schedule TO is hereby amended and supplemented by adding the following exhibits:

“(a)(12) Press release issued by Shire dated April 18, 2007.”

SIGNATURES

After due inquiry and to the best knowledge and belief of the undersigned, the undersigned certify that the information set forth in this statement is true, complete and correct.

Date: April 18, 2007


	SHUTTLE CORPORATION

	By:	/s/ Matthew Emmens
		Name: Matthew Emmens
		Title: President


	SHIRE PLC

	By:	/s/ Matthew Emmens
		Name: Matthew Emmens
		Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit No.		Description
(a)(12)		Press release issued by Shire dated April 18, 2007.

EX-99.A.12 2 dp05349e_exa12.htm Unassociated Document

Exhibit (a)(12)

Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com

Press Release

Shire Successfully Completes Tender Offer for New River Shares

BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, April 18, 2007 – Shire plc (LSE: SHP.L; NASDAQ: SHPGY; TSX: SHQ) (“Shire” or the “Company”) announced today that its wholly owned subsidiary, Shuttle Corporation (“Shuttle”), successfully completed its tender offer for the outstanding shares of common stock of New River Pharmaceuticals Inc. (NASDAQ: NRPH) (“New River”). The offer expired, as scheduled, at 12:00 Midnight, New York City time, on Tuesday, April 17, 2007. As of the expiration of the offer, a total of approximately 35,717,806 shares of New River common stock were validly tendered and not withdrawn (not including shares delivered through notices of guaranteed delivery), representing approximately 96.4% of the outstanding shares of New River common stock. Shuttle has accepted for purchase all shares that were validly tendered during the offer.

Shire intends to complete the acquisition of New River through a short-form merger without a vote or meeting of New River’s shareholders, after which New River will immediately become an indirect wholly owned subsidiary of Shire. In the merger, each of the remaining shares of New River common stock (other than shares as to which appraisal rights are properly demanded under Virginia law, if any) will be converted into the right to receive the same $64.00 in cash per share, without interest, that was paid in the tender offer. The merger is expected to occur within the next several days and a subsequent press release will be issued at that time. Following the merger, New River’s common stock will cease to be traded on The NASDAQ Global Market.

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+44 1256 894 160

	Eric Rojas (North America)	+1 484 595 8252

Media	Jessica Mann (Rest of the World)	+44 1256 894 280

	Matt Cabrey (North America)	+1 484 595 8248

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire

Registered in England 5492592 Registered Office as above

believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

“SAFE HARBOR” STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development, manufacturing and commercialization; the impact of competitive products, including, but not limited to the impact of those on Shire’s Attention Deficit and Hyperactivity Disorder (ADHD) franchise; patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise; government regulation and approval, including but not limited to the expected product approval dates of SPD503 (guanfacine extended release) (ADHD) and SPD465 (extended release triple-bead mixed amphetamine salts) (ADHD); Shire’s ability to secure new products for commercialization and/or development; Shire’s ability to benefit from its acquisition of New River Pharmaceuticals Inc.; and other risks and uncertainties detailed from time to time in Shire plc’s filings with the Securities and Exchange Commission, particularly Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2006.

GRAPHIC 3 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`$0`W@,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/WY;K0`E`!0`4`%`"$@#J``,\\``R=X;G3/!IMI-*LKF-BKV^H>)+F1;*.56&&2T^VNIX= M5(('UF5\&YMCXQJSC'`8>6JE6NIR3ZQI)I)=([+U> MWW7/C#6?^"J_CAIW.@?"'PG8V>?W8UOQ+JVH7`7/_+0V-C9Q[B/3CZU]32\/ M,)%)5LRK2EU]G2A!?+FE)G&\TG]FC&*\V_T2"'_@JIX^CM9EO/@[X3-ZT6;. M6'Q+K4%HLAQB2>WFTUY)8?O_`"QS(>GS<$T/P\P?,N7,ZR@GJG2A?T34DD_5 M?(%F=1+^#%/IJU^%B;X<8 M^S<8^:32ZM!3Q>)K2Y8U*5%]$TU?TO?7[CZ9U_Q%^WS\%;&Y\9^*5^%'QS\& MZ-"]_P")-'\)Z=>^&O%-II%N!)?WNF)]DMEG>"W620JL5XV$9C$54D>#1H<' M9I..%PWUO*,34?+2G6E&I2]*UWIO'?>YTN6.H+FER5X1U:BG&5NK6W MZG2_$K]O_P"%'PS?P3]L\->--=MO'?@/0OB#I%WHL&C&"/2M?:Z2WM+H7VJV M[I?PR6DR2HJLH88#'G'/@.#(J8><9N:?/3LVURP:Y7S*SW? M8JICZ5'D]V5IQ4E:VS^:U,?X<_\`!17X5?$GQWX3\`:1X+^(%AJ?B[6[30[" M\U&WT!;"UN;UF6.6[:VUN658!M.3'&[>@-:XW@C,,!@\3C*F*P\J>&@ZDHQ= M3F:6Z5X)7]6A4\PI3G"G&$DY.RO9)7^9^@M?&'>%`!0!YM\7?B;H_P`&OAUX MD^).O6&I:EI'AB"SGO+'2%MFU&=;W4K/3(Q;+=SPPEEFO8V.^5/E5L9.`>[+ M,!5S/&T,#1G&G4KN2C*=U%6C*;ORIO:+V6YG5J*A3E4:=H=%OJ[>7<^$/^'I MGP9_Z$#XF_\`@-X:_P#F@KZ__B'V:?\`09A?OJ__`"LX?[3H_P#/N?X?YGW? M\(?B=H_QC^'7AOXDZ!8:EIFD>)H;V>SL=76VCU&!;+4KS3)!-KX&K.,ZE!Q3E"_*^:,9JUTGM+LM3NHU%5IQJ13BI M7LGOH[=/0])KA-`H`*`"@`H`*`"@`H`*`%;K0`E`!0`4`%`'Y$?\%&?VGM9\ M/W:_`3P+JDVD23Z9;ZC\1M8L9VM[W['J:>9IOA6VN8RKVD=Q9E;N]=W- MM`&"23*_Z3P1D%*K'^V,73511DXX:$E[O-'255K9VE[L%LI*4MU$\G,,2X/V M%-\NEYM:;[1\N[^7F?G+X3_9\\3W_AVT\=>.K^Q^$GPXNW6/3/$GBVUO#JWB MF5B`EAX`\%6+[^5F58_(BAMLNI>Y53FOM\1G.'IUY8/!PEF..A\5*BX MJ%%=98BO+]W1BNMVY=HMGGPP\N53F_8T^CE>\O*,5JW^'F?3&D?L;_&G5=-B MN?A5\'O[`L98]T'C7XT:WH5KX[U-2H9+K3?!J-H'&^[5L M@>%4XGRJE-QS#,_:SB]:&!A4>'AY2K^[.NUU:E&#Z0.E8.M;]S1Y5_-4:4OE M'51^YOS/G_XI_LI_M$_"RQN_$GCOP'J4NC0`SZCXDT?4;/Q1I]HC,`;C4I]- MN)9[&'%]!EO?!VM:NS7$VM>'%5;&33]8CFF$I^SPM>HHUJ<-%3J_%S06T542 MEIM&:TTDDO:P&(E.,J,G[\%[K?;:S]/Q1\6_\%`_"EGX$^)7PR\%Z<5-EX6^ M"GA+0X'5?+$HL-4U^&2?9GY#+*LDI7L9"*^IX,Q$L7@/@J=2E!;0IQ7W-_F>'?LI?\G*?!'_`+*'H?\`Z,DKUN(?^1%FO_8- M4_0QPO\`O%'_`!(_J)/4_6OP`^E"@`H`^:OVP/"GB3QM^SE\2_"WA#1+[Q#X MBU2QT:/3=&TU(WO;UX/$NC7[PSB*&#SO`U\35 MC0H4Y3R>[:6W4YL7"4L/4A"+%/$O@?]G+X: M^%_%^B7WASQ%I5EK2:EHVI)''>V3W'B36+J%9TBDD0%[:>&08<_+(._%?C_$ MV(H8K.\=7PM6-:A-PY9QORNU*"=KI=4UMT/21^;/Q6_;)\6_$' MQ3/\%OV/=#;QOXPFW6VK_$;R4?PSX:A,GDW%YI;4O`G@ M#5+A5D2_UB.=C)J^KQ@*8H;DF=E",L6GQB-I/I,(\RX@A"E@X/(>'*?NQ]FE M#$8B"TY86TA!]7'W=[NH[VY)JE@VW-^WQ3U=_A@^[[O^M#SW]F'XCW/Q3_;" M^'WC#XX^)/[=O);K6&T>?6Y(H-(T_7QI-])X9T[2['Y+32+2/42GV2V@2-?M M*VWWI#N;MS_`QR[AG&87*:'L()0YU33YY4^>/M92E\4VXWYY-OW>;H9X:I[3 M%TY5I7>MKZ).SLDMEKLNY_1%7XIMY6/H"*>""Y@FM;F&*YMKB*2"XMIXTE@N M()D,39RW M,MFH9`0+4#G&3^U93Q3E<\MP(Z?`/_(FK?\`85/_`--TA9E_'C_@7YL^8_V4O^3E/@C_`-E#T/\` M]&25[_$/_(BS7_L&J?H<^%_WBC_B1^XOQ^_;;^$'P%OKCPW<27WC7QS;@&X\ M*>%WMBVELP#*FO:O<.+72964Y^S_`+^Y`P3`%8$_DV3<*9EF\(UXJ.$PCVJU M;KG_`.O<%[TUYZ1_O7/:KXRCAWRZRFOLQZ>KV7Y^1\9)_P`%7+\7I+_!&V_L M[=\J)XY<7P3(Y+-X;\DOMSP`!DCGU^H_XAW!1LLU?.O^G'N_^G;G'_:CO_`L MO\6OY'U[\!OVZO@]\;]6M/"FW4_`/C:_)33O#_B=K4VNKSX+?9=%URTD-M>7 MA`8K;3+:SR8_=QN<@?-YOPCF>44Y8A\ES175HZZ& M-HUFH:TY]$_T:T^6C/H_XL_$S1/@Y\/?$?Q'\16FI7NB^&(;.>]M-'B@FU&5 M;W4;33(Q;17-Q!$S">]C9MTJ?*K$9(`/AY;@*N98VA@:$HTZM=R47-M15HRF M[V3>T7LMSHJU(T*$/% M&JQ:18Z9;V>FGQ!#<37VJV"O=6SZHMLD/FZ1<$E+ESM>/C)(7QJ/#6-JYQ7R M6%6C'$X>#G*3E)4[*,):/DYKVFOLKJ;O%4X4(U^67))V2LK[M=[=.Y\_G_@J M-\"E!/\`PB'Q/`49_P"03X?X_P#+BKV?^(?YOTQ.%_\``ZG_`,K,/[3H?R3^ MY?YGV-\1OCW\,OA+X'TWQ[X\UY=$TS6;*UN]%TSR_M7B#6);NTCO4L=+TBV9 MI+NZ6*5/,92(8BP,LJ*0Q^8P.38_,,74P>#H^TG2DU.5^6G346X\TINRBF]O MM/HFSKJ5Z5&"G.7*GLNKOK9)?\,?G-XB_P""K=E!?R+X5^#-Y>:1%(^+KQ!X ML@TS4+F%2V'6QT[2;V*T=EP0K7,V.]?;T/#N7(OK&:1A4?2G1@Z5KK6\DRN+--3T^ M"_:%Y]J*XA6?:9-J@[-V!G`_.J]%T<16H)\SI5)T[I6YN63C>VN]MCU(N\8R MVYDG]ZN?%_Q>_P""A/P)^&%]>:'HDVI_$WQ%82O!=6O@_P"R_P!AVMQ&Y26" MX\37DJVDDBL.?L*WH'()##%?4Y9P7F^.A&K54&_ M*1L;>,,.#SSQ]`O#N"C9YJU/RH+E7R]K^?"[_@I5\%O M&E];:1XVTK7/A;?7,B0PW^KR6^L^&/-?Y0)]:TY4ET]6<@"2ZLHHESEY5`S7 MCYAP)FF#A*IA*E/'PCJXPO3JV\JD9-]DS>EF-%M1FG2?=_#]ZV^X_0^S MO+2_M;:^T^ZMKVQO((KFSO+.>*YM+JVG020W%M<0,TJ?=,]!-633TZ6+%2`K=:`$H`YKQ?XP\,>`/#FJ M>+?&&LV/A[P[HML]UJ.IW\HB@@C7[J(H!>>XD?"101*\DKNJ1JS,`=\-A<1C M*]/#86E*M7J.T816K;_!);MNR2U;L3.<:<7*348QW;T_K]3\H-7\:_&7_@H+ MXKO_``5\.FU/X9?LVZ->K;^)O$UQ"\>H>)$B8/Y%Z(Y%6_OIDVR1:%%+]GMU M>.749';RTK]%I87*^"\-#%8U0QN>5(WI4D_=I7ZQ_EBGHZS7-+54TM6>6YUL M=)PI7HX>.[V;_P""_P"79=3]+_A!\%_A[\#?"D'A'X>Z)%I=FOER:EJ,NR?6 MM=O538VH:UJ.Q7O+D_-M7Y8H@Q2&.-,+7PF99IC3;U/1HT:>'@H4X\JZOJWW;/Q<_P""BGP-U?P+\6KSXJZ=I\K^"?B5 M);7-SJ$$1:WTGQC#:QVNHZ=?NHQ`U_':QWUN[X$K2W,:DM"0?U+@G-J6+RV& M73FHXK`II1;UG1;;C**Z\C;A)+9C/'S"@Z=5U4K0J=>TNJ\K[KYGYW#@@ M@E2I#*02I5@0592,%6!`((P01D5]K_7WGGGU;\-?VV/VC?A?#;:?IOCJ3Q-H MEHL<46B>.;8>([>*"+`2WM]1FDCU.VB"C:%2]VJ,`+Q7SN.X5R/'.4YX-8:K M*[<\._9.[ZN*3IM_]N:G52QF(I649\T5TEK^.Z^\^WO`W_!52U(@M_B7\*+F MV;OBS/;Z=X<\>6>E:[&-7DD.,16RZB5M;Z8LI:,)\LND9>Z_QT^YGT]TXZ8_#&:\`Z3\$O^"GO_)?O#G_`&3+ M1?\`T_>(Z_8.`?\`D35O^PJ?_IND>%F7\>/^!?FSX#\)^*=:\#^)-'\6^'+I M;'7O#]V-0TF]:))?L=\D4D<-TL3_`"M)$93(FX$!T4D$#!^RQ&'I8JA5PU>/ M-1K+EG&]KQ;3:TV3M9^1PPDZC: M\\VI6WB'QSK,NG7/B%[IVGEU2WMDM;N^NX;F5VD%Y-%&DQZ'9-H.I7'V.Q\3>'[_\`M70WOBCRK8W,Q@@GT^\> M..5XX[F",2B)_+9RC`=>59_EF<.4,%5E&M37-*E4CR5%';F2NU*-VKN+=KJ] MKD5L+6PUN>-H[)IZ7[=+'S]!-/:307-K-+:W5K-%(?J9\1_P#E&'\(/^QWLO\`U(_'%?G^!_Y+W,O^O$O_`$W0/3J?\BVC M_B_]ND?EF1D%>@/''8'KBOT!:?(\P]4^+/Q3\4_&?QE%K^M-=Y-"I[.6:X6,D[6]O#1^ MM[?B/ZO7M=49VZ>ZS[9_;%_:AU^#PSX2_9V\$WUYHEKH'@CPI9?%*^MI)+34 M;O6#X>L!-X)+H5DM;2S1E_M&,%7DG?[*^U;>99?E>&.'Z/M\3G>*A&I*M7K2 MPD7K&,/:2M7MLW)_PWLH^^M91:[,7B9*,,/3;BHQBIM:.]E[OEY^>A^?'P^^ M'?C+XG^)].\%^`-`NM?\0:AN,%C:".*&VMHMOGWU_=S,D&G:="K*9+B9T1=R MJ"695;[/&8W"Y=AYXK&5E0HT]V]VWM&,5K*3Z12N_2[."G3G.2A3C>71+3Y^ M2/O.W_X)>?'632A>3>,/AG:ZGY7F?V*U[X@E*R;0?(;4HM%\D29RNY49.,[L M&OD'Q_E$:G)'#8ITT_CY::^?(ZE_QOY'O[3FI^#/&&F_!#Q?J4MSX)\7W/V3P=+>3/)_PBGBB;+6VFVKN3Y6BZM)F$ M6XPD5X\+QA1<39^/XTR"GB<+/-<+34,7A5S5E%6]K26\FE]NFM;[RA=.]HG= M@,2Z#OV??` ME]'>7$*!4:VMGW1VTMT1NAO_`!QJL:S>2CF2+3;=Y64,58W?ZBH8'@;+%4M# M$9SBXN*?=[M+K&A3=N9JSJRLM/L^/>ICZW*KPP]-_=_]L^G9?C^RW@CP3X7^ M'/A?1_!G@S1[70O#FA6J6NGZ?:+M55',D\\AR]S>32EI9KB5FDEDD9W8LQ-? ME^+Q6(QN(JXK$U'4KU7>4G^"2VC%+116B6B/8A"-*,807+&.R7]?\.=57.48 M7B7PQX>\8Z%J/ACQ5HVG:_X?U:W:UU+2-4MH[JRNX7YQ)%(#AU8!TD7:\;JK MHRLH(VP^(K82M3KX:K*A6I.\9P?+*+\FN_5;-:.Z)E&,HN,HIQ>Z>Q^5WQ;_ M`."76DWMQ=:K\%?&O_"/B5WE3PCXS2YU'2H206\G3_$-FKWUM#N^5$NK>]*C M&9>,U^A9;Q_4IQC2S3">VY=/;4+0GZRINT&^[C*'H>95RQ:NC/D_NRV7HUJO MFF?`WCG]B_\`:6\`&9]2^&&K:Y80!G.I^"Y8/%5H8@3^]-OIK&^B7')$EFA` M/-?883BC(L994\?"A-_8KIT6GVO+W'\I'#/!XBE_RZ;2ZQU_+7\#YEOK*]TF M[DL-3L;W2K^$E9;'4K2XT^\C93A@]K=QQRH0?5:]Z$H2BI4I1E#I*#4H_?%M M',TXNS7*^ST_`JE1QD#@@CC&"#D$>A!Y!%5MMH(_5+]A/]L7Q+I'BG0O@I\3 MM9N-;\+^(9H=(\$^(-6N'GU/PUK,G[O3M$N[^9FDO-#O7V6T'G,SVL[PJK^1 M(5B_/>+N&*$\/6S3+Z2H5Z"Z?1>C_!^1Q?_!3W_DOWAS_LF6B_^G[Q'75P#_R)JW_85/\`]-TB M,R_CQ_P+\V?$GPD\*0>.OBG\.?!=U_QY^)_&WAK1+T9VYL;_`%:UAOAGWM&F M''//'-?5YEB'@LOQV*CI+#4*M2/^*,&X_P#DUCCI04JM.&RE)+Y-ZG]8-K:V MUC;6]E9P16EG9P0VMI:P1K%!;6UO&L,$$,2`+%%'$BJJJ``%`'2OYUE*4I2E M)N4I-MMZMMN[;?=O<^I2222T2V/GW]K3PQ9>*_V;_C#IMY#'*+/P3J_B"U,B MJ3;W_AF$Z]9W$3-_JY4ET\8(P2&9>0Q!]KARO+#9YEDX-QYJ\*;MI>-5^S:? ME:1SXJ*>'JQ[1;7DUK^A_+\.@^E?OI\T?JE\.KB67_@F!\6HG.4M/&%_!`.? MEC;Q5X-NBO)X'FW$IXQU]:_/<;%1X^RYK3FHQ;]?8UU^21Z=/_D655M:3_\` M2HGY6U^A'F'ZF?$?_E&'\(/^QWLO_4C\<5^?X'_DO8?NK_`,$ZOV>/#OAKX=:?\:]?TJUO_&GC1KN;PW=7L$<[ M>&_"]M=2V=LVF+("+6_U&:WFN9;E0)#`]O$K*OF"3\DXVSJO6QT\JH5'3PN% MLJBB[>TJM*3YK;Q@FHJ.W-S-W=K>WE^'C"FJS7OR^'^ZO+S>]^Q^B_BK7H?" MWA?Q)XFN`&M_#N@ZQKLREMH:+2=/N+^12>VY8"/QKXC#T7B,10P\='7J0IKU MG)1_4]"4N6,I=(IO[E<_DGUO6M0\1ZSJ_B+5IY+G5->U2_UK4;F4DR3WVJ74 MM[=2N2E2H4ERTZ$(PBEHE&*44ON1\K)MRI^ MBG[#?[1'[/\`^SWX9\7WGCZXU^#Q[XGUF*#SM,\+7NKQ6_A73K6!M/M8K^V! M$9FU.?49IH1C/E6Y;.Q=OQ/%F29SG-?#0P<:?U/#0;M*K&#=6;?,W%]HJ*3\ MY6W9Z&"Q&'PT9\]U4D^BO[J_X-_P/NO_`(>2_LO_`/07\:_^$/K'^%?(_P"H MN?\`_/JA_P"#X'=_:.&[R_\``6?#W[W+ M)6:^:;/.3:::T:U7R/ZT?AYXG7QIX"\$^,$V@>*/"GA_Q`0G"H^KZ5:WTB`# MIMDG9M4I_P#@$W%?>D?4TYKG8MUKE+ M/PI_;H^.FO?&[XKZ9^SW\.99+SP[H'B6QT&6VLY3Y7BSXB7-RNGXE9#MDTW2 M;BX-K&#E?/6\G.0D13]G&G'2V[VN^K_KH>QUYAL)[>Q_M*?P MYXK"FY6OR*]KJ_'O%5E)&8\:OIL$]U`""`UGJ"JMU82C)Q);S1.O4, M*[,'F&-R^:J8/%5,-*.ON2:7_;T?ADO*2:(G2IS7+.":\U^3W7R/Y^?VTOV; M-*_9T^(.D6_A2[N[CP3XTTZ\U70;;49OM%_HMSI]S'!JFC2W9PU[;1?:;.6" M>0>84N3'(7:$R2?LO"V>5,YP51XB*ABL+*,*CBK1FI)N$TMHMVDI):75U9.R M\'&8986HE!^Y)-I=K;K\=#X_L[RXTV\L]1LY'AN]/N[:_M)8R5DBN;.>.YMY M(R""'6:-&&".0*^EE&,XRIR7NR3BT]K25FOFF68RFMJ>-K17I M&--+\CNS!WK4WWIQ?XL^>OV4O^3E/@B/^JAZ'_Z,D[5[7$6F19MTMAJGZ&&% M_P!XH_XD?U$GJ?K7X`?2GCW[0O\`R07XU?\`9*O'_P#ZB^IUZ>2_\CC*O^PO M#_\`IV!CB/X%;_!+\F?RK#H/H/Y5_0I\P?J7\-?^48GQC_[':]_]2+P-7Y]C MO^2]RS_KQ'_TW7/3I_\`(LK?XG_Z5$_+2OT$\P_4SXC_`/*,/X0?]CO9?^I' MXXK\_P`#_P`E[F7_`%XE_P"FZ!Z=3_D6T?\`%_[=(_+)ONGZ'^5?H!YA_5'^ MSE;PVGP"^#4$""*)/AKX.947@!I-#LY7/U:1V8^[&OY[SQO^V,T;>OUJM_Z< MDCZ?#JU"BEHE"/Y&W\:K.>_^#OQ6L;5"]Q=_#CQM;P1KU>67PWJ2(@X/+,0. MG>LLJE&&9Y=)NT88F@WY)58W*K+]S52_DE9?)G\H"?<3_=7^0K^B6?+'UA\# M_P!CGXJ_'_PC=^,_`NI>"K;2K'7;OP]<0:]J^H66H)?V5I8WLC?9[32+I1;M M!J-N463E'=SCK>+OH=5#!U M:T'.FXI)VLVT[Z/HGW/8_P#AV/\`M%?]!?X8_P#A0ZW_`/,W7F?Z^Y)_SZQ7 M_@NG_P#+3;^S<1WA][_^1#_AV/\`M%?]!?X8_P#A0ZW_`/,W1_K[DG_/K%?^ M"Z?_`,M#^S<1WA][_P#D0/\`P3'_`&BO^@O\,?\`PH=:_P#F;H_U]R3_`)]8 MK_P73_\`EH?V;B.\/O?_`,B?M3\$_!VL?#WX1_#KP/X@EM)M;\*^$M'T/4Y= M/GEN+)[NPM4@E-I/-%%))!E<*6C0X`^45^69KB:6,S+&XN@G&EB*TZD%))22 MD[JZ3:3[V;/8HP=.E3@]X12=MM"Q\9O%MSX!^$_Q(\9V(/V[PSX*\1:OI^,? M+J%KIER]BY!ZJMWY3'V4TLKPT<9F.!PLM(5Z].$O\+FN;[U<=:?LZ522WC%M M>MM#\%/^"?\`I5GXB_:H\'7.M.MS<:=I_BWQ+`;EB\EUK<&DW`CN"6!,EPLE M[/=;B<[H=V/I9E@,-C:35JT%S)?8 MJ+2I!^<97]59]3Y>M2="I.FU;E>G33H_N.J_9U^/?B/]G;XB6WC;0[5=5TZY MMFTCQ3X=EF-M%KFAS31S20QSA6%KJ-O/&D]M<%6"2(5=6BED5N?.\GH9U@I8 M2K+V4XOGI5$KNG42:3MUC)-J<=+K5--)E8>O+#5%.*TV:VNOT?8_<_P+^W?^ MS-XUT^WN9OB!:^"M1=%-QH?C:WGT.\M)2H+QB[9)+"[4-D![>[D!`S@9Q7Y) MB^$,^P*IQVJ4&IQ:_PZ3C?LXH]NGCL-)+W_9OM+2WZ?B;GB7]M;]F# MPM8RWEQ\6O#VK21QF2+3O#/VOQ#J-R1G$4-OI=O*J.QX!F>)1U9@.:RH<*Y_ M7FH1RVI25[[[W;] M6X2G6E'X4TK1A"]FXQ5]6DY-MV2LCQL5B/;U$TN6$5:*Z M^;?FSR/X-_#G5/BQ\4/!/P^TB"22;Q#KME#>R1HS+8Z+;RK=:YJ4^T'9!;:7 M%*[07YL^:/V4O^3E/@C_`-E#T/\`]&25[O$/_(BS7_L& MJ?H<^%_WBC_B1_42>I^M?@!]*>/?M"_\D%^-7_9*O'__`*B^IUZ>2_\`(XRK M_L+P_P#Z=@8XC^!6_P`$OR9_*L.@^@_E7]"GS!^I?PU_Y1B?&/\`[':]_P#4 MB\#5^?8[_DOYE_UXE_Z;H'IU/\`D6T?\7_MTC\LF^ZWT/\`*OT` M\P_JI_9Y_P"2#_!O_LF?@O\`],%C7\]9U_R.,S_["J__`*AKS4W%J479Q::?9K5&MN MG0_E7^._PMU+X,_%CQG\/M0@EBATG5KB?0KB12JZCX:U"1[K0=0A;HZO8O'& MY&=LT$T9PT9`_H7*,PIYGEV%QE-I.I!*HE]BK%6J1?I+5=XM/9GS%>DZ%6=/ M91>G31[/[CZO_8(_:@\.?`_7_$'@GX@WC:7X&\:W%G?VVO,DLMMX;\1VL9M/ M.U".(,T6E7UF8HY9U1_)DLH&<"-I'3YWC#A^OFM&CBL#'FQ>$4HNGHG4I2=[ M1O9<\)7:5US*4K:V3ZL#B8T)2A4?+">M_P"5^?DS]SK#XA^`-3T]=6TWQOX0 MO=+:)9AJ-IXDT>:R$3#<':XCO"B+C^\1CO7Y+/!8RE/V4\)6IU+VY72FI7]. M6Y[2J4[74XV[IJQ^?7[67[>_A[P)IC>#_@3XDTGQ'\09;R#^T/$MC!::YX:\ M,65O,)+J!9Y0]GK&KW*H(!'"9HX(YI)'=95C0_9<.<'5L546)S:A/#X)1?+2 MDW3JU9-63LK2A"-[W=G)I))J[.#%8Z--&,!A,1C*V%J1I8:$IO_:*JO9>[%>]O*5HI=6T<=/&8NZ MOF]NBU/W\MXY8K>"*:IA,10Q-%\M7#SC4AVYHM25UVTU[HF<5*,H/ MX9)IKR9^#>O?L??M2_LW_$?3_&GPITB[\

&M5:^\+^)_"J6U[>RVI5XS:> M(/"TTZ72F:RFDMKN")+B"59)1'+AAM_7Z/$O#^=X&>$S"I'!.O#EJTJMXQ3W MO3JI!_VQ/C5.O MV.?C1%K2;([N\\(:+=2Z7-(5#&6*T\00VFY*7JHQ]#OABZUDIX2I=?RK3[G:WWGONC_%OXQ^)L'1? MV;/$_A^!SA;[XC^-_"'A>&(-TDFT_19M=U+`X)5;//;.:\>IEN5X;^+GE*JX M_9PU"M5?RE-4:?\`Y,;QJUG\.&<%_?E&-ODN9_@>G^'['XDS75O?>+M<\+V$ M$1D+^'/"6E7EQ!+N5EC6\\1Z[/Y]RJ,P;_1=-TXDH,DJ2I\^M+`0C*&%HU9/ MI4K3BFN_+2IJR_[>G/MP_P`18G(: MTE&/M\'5:=6C>VJTYZ;^S-+3:TEI+9-8XG"PKQ7V)QVE^C\OR/PA^*_[,/QO M^#-Y<1>,/`NJS:3"Y$'BGPY;W&O^&+J+)V2C4;"%FL2RC)BOHK61<\KWK]>R M[/\`*'5PU:@[2INR^U'6/WK;YV/G[S M802OF1J5."I90RGT*DY4_45[-FMDTC#;R$$T*D`21`]`H=`M;O+*21$F\0ZE:S:+X8LD;DS7&M:C''#(JKEO+MOM M$K8PD;'BO*S#.LKRJ+EB\93IRBM*<6IU7Y*G&[7K+E7=HVI8>M5=J=-V[O1+ MYO\`0_=W]E']D7PU^S=I-UJ=W>P^)_B3KMK';:YXE6!H;+3[,,LS:'X<@E'F MV^G>>J/+/+B:Z>*-G$:HD4?Y#Q%Q)7SJI&G"#PV!HMNG2O[TI;>TJ-:.5M$E M[L4VE=MM^YA<)'#)N]ZDMWM9=DNB_,_.W_@I;X<\2:M\>/#USH_AOQ%J]LOP MVT>%KG2=!U;4[99EUSQ$S0M<6%G+&LH5E)0L&`=21@C/VW`E>A2RBM&I7I4I M?69OEG4A!V]G3UM*2=O,\_,8R=>/+%M3=+<7-QIZ101#N[LJCN:]WB#$X9Y'FD88FC M*3P\THQJTVVW;1)2NWY)'/A836(H^Y))27V6K?@?TTGJ:_!CZ,\C^/T$]S\" M_C);6L$]S%6DFF=R%5$5F8D``DUZ63 M-0S?+')J,8XK#MMM))>UC=MNR2[MZ&5=?N*R2^Q*R^3/Y=QX(\<8'_%#>-N@ M_P"90\1__*ROW_ZUA/\`H+H?^#J7_P`D?,\D_P#GW+_P%_Y'Z=_#GP_X@A_X M)J?%[2)?#VOPZO/XSO)(-'ET35(M6GC/B'P2XD@TQ[074T92.1MR1,"(W.<* M2?*MUU['I4XR66U8\K3YG96:>\>FY M^8O_``A'CC_H1O&W_A(>(_\`Y65]]]:PG_070_\`!U+_`.2/-Y)_\^Y?^`O_ M`"/T[^(GA_Q!)_P33^$ND0^'M?DU>#QI9R3Z/%HFJ2:M;QCQ#XU.=K?\4-XVZ'_F4/$?I_V#*^^^M83_`*"Z'_@Z ME_\`)'F M9-!L5DAG@F59(958$,CJK`@@@$5^`9RT\VS)Q:<7B:S33333J2U36C7FCZ:@ MK4:2M:T(Z;6T7W'KM>::GR3^U;^REX=_:1\.6DD5W!X<^(?AR"=/"_B=X6EM MY()6,LF@Z]%$/,N-&FF^=73,MK*S2Q!@\L4WTG#O$5;(:\ERNM@J[7M:5[-- M:*I3;T4TM'TDM';1KEQ6%CB(K[%2'PR_1^7Y'X%?%'X"?%WX-:C-8>/_``/K M.DP1R.D&NVEK+J?AF_13Q-9:]8QO;%&7#>7,T,JYP\:GBOV++\WRW,H*>"Q< M)NVM-M0JQ\I4Y6E\TFGT;/"JT*M!\LX.*[KX?DUH>+;K(!EW6ZAC\R[HU#'O MN7."?J*]2TE;1JVWD8Z+R._\"?#7Q]\2]3@T7X?>#M?\57LSJBKH^FSRV5N& M('F7FI,B6>GVZYRTMQ/$B@$D\5QXO'8/`4W5QF)IX:$?YY)2?E&/Q2?E%-ET MZIW!"K=WRA5*H((/W6][C\BXHXG><26$PBE1RZE+F][2=::VE)+ MX8K[$-[OFEK91]S!X-8;WYV]JU;3:*[+S[O[O/[ZKXX[A6ZT`)T]L?AC-`!D M^IH`*`"@`H`"!@K@$8(*D9!!X((Z$8H`X/5?A7\,-2:[*>88^BN6CCL12711K5(K[E)(ATJ3WIQ^<5_D1Z M;\)_A9HLHGTCX:^`=+G5@RSV'@_P_:3*PQAEE@T]64\=C3GF.837+4QV(FNT MJU1K[G*PE2I1^&G&/I%+]#OE5458T541`%1$4*B*!@*JJ`%`'8"N(TVT6EOD M.H`,X]L?AC-`!D^M`!0`=/;'X8S0`9/J:`"C;RL`9/J:`"@`R?4T`%`!0`4` M,EBCFC>&:..6&12KQ2HLD;J>JO&X*LI]"*:;BTXOE<=FM&O\@\CBI?AC\-9K MC[5-\//`TMT"3]IE\):`]P"V=Q\YK`OD[CGGN?6NI8_'1CR1QM>,>RK5$ONY MK$>RI_\`/N/_`("O\CK;*PL=,MTM--LK33K2/_5VUC;0VENF>NV&W1$7\`*Y ;I3G-N4Y.4N\FV_O>I22CI% -----END PRIVACY-ENHANCED MESSAGE-----